Skip to content
Pharma Observatory a Scientist.com platform

Organization (Nonprofit)

Wake Forest University Health Sciences

ClinicalTrials.gov lists Wake Forest University Health Sciences as lead sponsor of 1,345 trials. It has 571 active development programs and 281 approved assets.

US Nonprofit
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

102 0 1993 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 88 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 73 in 2026 and about 78 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (20 to 100), forecasts made part-way through the year were typically off by about 18 percent and ran about 14 percent low against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 88 already registered with a 2026 start date: at the cutoff, 35 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts. 14 trials are registered to start in 2027 or later.

This page covers Wake Forest University Health Sciences: 1,345 lead-sponsored trials and 1 legal-entity registration. Part of Wake Forest University.

Get the Wake Forest University Health Sciences report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (579)

Shown in this order: most trials first (counted at this company's own legal-entity record, not the consolidated group).

Trials by start year as sponsor or collaborator (33)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 14 trials are registered to start in 2027 or later, and not listed here.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 88
2025 79
2024 86
2023 97
2022 73
2021 102
2020 84
2019 99
2018 92
2017 77

Prediction, not a registry value: median of 36 months from start to primary completion across 121 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 992 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (571)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
CARBOPLATIN Lung Neoplasms Phase 3 8
CARBOPLATIN Carcinoma, Non-Small-Cell Lung Phase 3 6
(nab)-paclitaxel Lung Neoplasms Phase 3 4
(nab)-paclitaxel Carcinoma, Non-Small-Cell Lung Phase 3 4
PEMBROLIZUMAB Lung Neoplasms Phase 3 4

Approved assets (281)

Shown in this order: max phase first.

Approved assets
Drug Trials
Oxytocin 14
+/- Bupivacaine HCl 13
Acetaminophen 6
DEXAMETHASONE 5
Gabapentin 3

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
35% hit target (n=645) 36% on time (n=565)

FDA inspection record (1)

FDA inspection record
Latest classification Inspections
NAI 2

CLIA clinical laboratory certificates (1)

CLIA clinical laboratory certificates
Lab Certificate Status
WAKE FOREST UNIVERSITY HEALTH SCIENCES Certificate of waiver Terminated

Biomarker capability evidence (1,264)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
ABCC1 Trial sponsor Named in trial inclusion criteria
ABL1 Trial sponsor Named in trial inclusion criteria
ABO Trial collaborator Named in trial inclusion criteria
ABO Trial collaborator Named in trial inclusion criteria
ACAT1 Trial sponsor Named in trial inclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and organization relationships.

Counted at group level under Wake Forest University: journals published in, us granted patents, latest dated events, and biomarkers this organization publishes on.